118 related articles for article (PubMed ID: 28854182)
21. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
23. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
24. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
25. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
26. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
27. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
[TBL] [Abstract][Full Text] [Related]
29. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
[TBL] [Abstract][Full Text] [Related]
31. ERG protein expression as a biomarker of prostate cancer.
Falzarano SM; Magi-Galluzzi C
Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].
Allina DO; Kekeeva TV; Moskvina LV; Shikeeva AA; Andreeva YY; Zavalishina LE; Frank GA
Arkh Patol; 2015; 77(5):36-42. PubMed ID: 26978019
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
[TBL] [Abstract][Full Text] [Related]
34. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
35. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer.
Yun JW; Lee S; Chun S; Lee KW; Kim J; Kim HS
Clin Transl Med; 2021 May; 11(5):e420. PubMed ID: 34047472
[No Abstract] [Full Text] [Related]
37. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
Wang J; Cai Y; Ren C; Ittmann M
Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
[TBL] [Abstract][Full Text] [Related]
38. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723
[TBL] [Abstract][Full Text] [Related]
39. The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells.
Kissick HT; On ST; Dunn LK; Sanda MG; Asara JM; Pellegrini KL; Noel JK; Arredouani MS
BMC Cancer; 2015 Aug; 15():604. PubMed ID: 26310325
[TBL] [Abstract][Full Text] [Related]
40. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
